Abstract 2424
Background
Prognosis of metastatic pancreatic adenocarcinoma is gloomy. To elicit a chemotherapy regimen with higher efficiency and with lower toxicities is critical important.
Methods
This was a one arm, phase 2, three-center study. Enrolled patients were histological or pathologically confirmed; treatment naïve metastatic pancreatic adenocarcinoma. Enrolled patients were 18 years or older, with at least one measurable lesion and performance status between 0-2 with ECOG score. Irrinotecan 165 mg/m2 and oxaliplatin 85 mg/m2 were administered intravenous infusion on days 1, and S1 40 mg/m2 was administered orally on day 1-14, every 21 day a cycle until progressive disease or intolerable toxicities or patient death. The primary endpoint was overall survival and the second endpoints were progression-free survival and toxicities.
Results
A total of 41 patients were enrolled, median age was 59 year-old. There were 18 men and 23 women. The median progression-free survival was 4.33 (95% CI: 2.83-5.88) and median overall survival was 11.00 (95% CI: 9.16-12.84). There were 38 patients validated for efficiency evaluation. There was no complete response, the partial response rate, stable disease and progression disease was 42.11% (16/38), 31.58% (12/38) and 26.32% (10/38) respectively. The most common adverse effect was mild to moderate nausea, vomiting, neutropenia and thrombocytopenia. The 3/4 degree neutropenia and thrombocytopenia were 29.27% (12/41) and 12.20% (5/41) respectively.
Conclusions
Irinotecan combined with oxaliplatin and S1 was effective in metastatic pancreatic adenocarcinoma; its toxicities were mild to moderate and tolerable. Furthermore, patients to enrol the study is needed.
Clinical trial identification
NCT03726021.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3330 - Tumour-infiltrating lymphocytes and BRCA-like status in stage III breast cancer patients treated with intensified carboplatin-based chemotherapy
Presenter: Leonora De Boo
Session: Poster Display session 2
Resources:
Abstract
3971 - Unravelling the biological characteristics of MammaPrint extreme risk subgroups
Presenter: Rajith Bhaskaran
Session: Poster Display session 2
Resources:
Abstract
5871 - Residual Cancer burden as a prognostic factor in a large series of Neoadjuvant chemotherapy. Subgroup analysis per molecular surrogated subtypes
Presenter: Catalina Falo
Session: Poster Display session 2
Resources:
Abstract
5014 - Clinical validation of CanAssist Breast in a Spanish cohort
Presenter: Manjiri Bakre
Session: Poster Display session 2
Resources:
Abstract
2787 - Meta-analysis on association of pathological complete response with long-term survival outcomes in triple-negative breast cancer
Presenter: Peter A. Fasching
Session: Poster Display session 2
Resources:
Abstract
4301 - Immune infiltrate composition across intrinsic subtypes in hormone receptor (HR)+/HER2- early breast cancer (BC) enrolled in the prospective LETLOB trial
Presenter: Gaia Griguolo
Session: Poster Display session 2
Resources:
Abstract
3205 - Frequency of germline mutations in women's cancer susceptibility genes in a large cohort of Chinese breast cancer patients
Presenter: Ning Liao
Session: Poster Display session 2
Resources:
Abstract
4091 - Triple blinded Prospective Study assessing the Impact of Genomics & Artificial Intelligence Watson For Oncology (WFO) on MDT’s Decision of Adjuvant Systemic Therapy for Hormone Receptor Positive Early Breast Carcinoma-
Presenter: Somashekhar Sampige Prasannakumar
Session: Poster Display session 2
Resources:
Abstract
4359 - Prognostic significance of Progesterone Receptor levels in luminal-like Her2- early Breast Cancer patients. A retrospective single Cancer Center analysis.
Presenter: Anna Diana
Session: Poster Display session 2
Resources:
Abstract
1369 - PAM50 HER2-enriched subtype and pathological complete response in HER2-positive early breast cancer: a meta-analysis
Presenter: Francesco Schettini
Session: Poster Display session 2
Resources:
Abstract